<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453375</url>
  </required_header>
  <id_info>
    <org_study_id>BHT-3021-01</org_study_id>
    <nct_id>NCT00453375</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic Study of BHT-3021 With Open Label Cross-Over in Subjects With Type I Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayhill Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayhill Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of BHT-3021 injections given weekly for
      12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to
      autoantigens (e.g. insulin). Changes in pancreatic beta cell function, insulin requirements
      and blood glucose levels will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes results from an attack by the body's own immune system on the insulin
      producing cells in the pancreas. Around 80% of diagnosed patients have detectable antibodies
      to islet cell self-proteins including, insulin IA-2 and glutamic acid decarboxylase. The
      drug, BHT-3021 is being studied because an agent that stops autoimmune damage could offer
      patients benefit.

      Study Description: A Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic
      Study of BHT-3021 with Open Label Cross-Over in Subjects with Type I Diabetes Mellitus that
      will enroll up to 72 subjects in this trial. Subjects will be randomized to BHT-3021 or
      BHT-placebo in a 2:1 ratio.

      The duration of the study is approximately 25 to 37 months depending on treatment assignment:
      4 week Screening Period; 12 month Blinded Treatment and Evaluation Period; 12 month
      Cross-over Treatment and Evaluation Period (BHT-placebo subjects only); 12 month Long Term
      Follow-Up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint in this study is safety.Safety parameters include: stimulated C-peptide response levels, opthalmologic examination, laboratory assessments, 24-hr urine protein, allergic reactions and adverse events including hypoglycemia.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints are pharmacodynamic parameters. Parameters include plasmid levels and insulin mRNA levels in blood and urine, Stimulated C-peptide response and Immunological response.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BHT-3021</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BHT-Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHT-3021</intervention_name>
    <description>Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHT-Placebo</intervention_name>
    <description>Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Diagnosis of Type 1a Diabetes Mellitus based on ADA Criteria

          -  ≤5 years since T1D was diagnosed

          -  ≥ 18 years of age

          -  ≤ 40 years of age at the time of diagnosis of Type 1a diabetes

          -  Presence of antibodies to at least one of the following antigens:

        insulin, GAD-65, or IA-2

          -  Detectable fasting C-peptide level

          -  C-peptide increase during screening mixed meal tolerance test with a minimal
             stimulated value of ≥ 0.2 pmol/mL

          -  Presence of antibodies to at least one of the following antigens: insulin, GAD-65, or
             IA-2. If insulin antibody positive only, determination must be within 2 weeks of
             insulin initiation

        Exclusion Criteria:

          -  BMI &gt; 30 kg/m2

          -  Unstable blood sugar control defined as one or more episodes of severe hypoglycemia
             (defined as hypoglycemia that required the assistance of another person) within the
             last 30 days

          -  Current use of inhalable insulin

          -  Previous immunotherapy for T1D

          -  Administration of an experimental agent for T1D at any time or use of an experimental
             device for T1D within 30 days prior to screening, unless approved by the medical
             monitor

          -  History of any organ transplant, including islet cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gottlieb, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Quan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bayhill Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Len Harrison, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Walter and Eliza Hall Institute of Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine, Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton Diabetes Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Glandular Disease Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-2795</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Clinical Research Centre</name>
      <address>
        <city>Kippa Ring</city>
        <state>Queensland</state>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Clinical Research Unit</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Otahuhu</city>
        <state>Auckland</state>
        <zip>Private Bag 93311</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>Private Bag 4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Regional Diabetes Service</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>Private bag 3200</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Diabetes Centre</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>Private Bag 7902</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bayhilltx.com</url>
    <description>Bayhill Therapeutics Inc., Click Here for More Information Regarding this Study.</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Diane Amend, Clinical Trials Manager</name_title>
    <organization>Bayhill Therapeutics</organization>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>autoimmune disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

